Progress a backup nitroimidazole into pre-clinical development
last phase of drug development
updated 31 Aug 2015
The nitroimidazole backup programme for HAT identified SCYX-2035811 as a suitable candidate for further exploration, and although initial results in animal models had shown excellent activity, further studies showed the doses tested to give insufficient cure. Given the progress of fexinidazole (Phase II/ III) and SCYX-7158 (Phase I), further development was put on hold in 2013, and the project has now been stopped.
Get our latest news, personal stories, research articles, and job opportunities.